224 related articles for article (PubMed ID: 7698284)
1. Inhibition of cholesterol synthesis ex vivo and in vivo by fluvastatin, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase.
Yamamoto A; Itoh S; Hoshi K; Ichihara K
Experientia; 1995 Mar; 51(3):223-6. PubMed ID: 7698284
[TBL] [Abstract][Full Text] [Related]
2. Species differences in the inhibiting effect of fluvastatin, a new inhibitor of HMG-CoA reductase, on cholesterol biosynthesis.
Yamamoto A; Itoh S; Hoshi K; Ichihara K
Res Commun Mol Pathol Pharmacol; 1994 Dec; 86(3):325-34. PubMed ID: 7712108
[TBL] [Abstract][Full Text] [Related]
3. Selective inhibition of cholesterol synthesis in liver versus extrahepatic tissues by HMG-CoA reductase inhibitors.
Parker RA; Clark RW; Sit SY; Lanier TL; Grosso RA; Wright JJ
J Lipid Res; 1990 Jul; 31(7):1271-82. PubMed ID: 2401858
[TBL] [Abstract][Full Text] [Related]
4. Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
Koga T; Shimada Y; Kuroda M; Tsujita Y; Hasegawa K; Yamazaki M
Biochim Biophys Acta; 1990 Jul; 1045(2):115-20. PubMed ID: 2116173
[TBL] [Abstract][Full Text] [Related]
5. Effect of fluvastatin sodium (XU62-320), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on the induction of low-density lipoprotein receptor in HepG2 cells.
Hayashi K; Kurokawa J; Nomura S; Kuga Y; Ohkura Y; Kajiyama G
Biochim Biophys Acta; 1993 Apr; 1167(2):223-5. PubMed ID: 8466953
[TBL] [Abstract][Full Text] [Related]
6. Tissue-selective acute effects of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase on cholesterol biosynthesis in lens.
Mosley ST; Kalinowski SS; Schafer BL; Tanaka RD
J Lipid Res; 1989 Sep; 30(9):1411-20. PubMed ID: 2513368
[TBL] [Abstract][Full Text] [Related]
7. Fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase, scavenges free radicals and inhibits lipid peroxidation in rat liver microsomes.
Yamamoto A; Hoshi K; Ichihara K
Eur J Pharmacol; 1998 Nov; 361(1):143-9. PubMed ID: 9851551
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
Aoki T; Nishimura H; Nakagawa S; Kojima J; Suzuki H; Tamaki T; Wada Y; Yokoo N; Sato F; Kimata H; Kitahara M; Toyoda K; Sakashita M; Saito Y
Arzneimittelforschung; 1997 Aug; 47(8):904-9. PubMed ID: 9296275
[TBL] [Abstract][Full Text] [Related]
9. Fluvastatin normalizes the decreased turnovers of glutathione and ascorbic acid in Watanabe heritable hyperlipidaemic rabbits.
Suzumura K; Kasahara E; Ohnishi Y; Chien KC; Inoue M
Clin Exp Pharmacol Physiol; 2000 Sep; 27(9):709-14. PubMed ID: 10972538
[TBL] [Abstract][Full Text] [Related]
10. Direct effects of statins on the vascular wall.
Corsini A; Pazzucconi F; Arnaboldi L; Pfister P; Fumagalli R; Paoletti R; Sirtori CR
J Cardiovasc Pharmacol; 1998 May; 31(5):773-8. PubMed ID: 9593078
[TBL] [Abstract][Full Text] [Related]
11. High dose of fluvastatin sodium (XU62-320), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, lowers plasma cholesterol levels in homozygous Watanabe-heritable hyperlipidemic rabbits.
Kurokawa J; Hayashi K; Toyota Y; Shingu T; Shiomi M; Kajiyama G
Biochim Biophys Acta; 1995 Oct; 1259(1):99-104. PubMed ID: 7492622
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effect of fluvastatin on ileal ulcer formation in rats induced by nonsteroidal antiinflammatory drug.
Hagiwara M; Kataoka K; Arimochi H; Kuwahara T; Nakayama H; Ohnishi Y
World J Gastroenterol; 2005 Feb; 11(7):1040-3. PubMed ID: 15742411
[TBL] [Abstract][Full Text] [Related]
13. Regulation of cytochrome P450 expression by inhibitors of hydroxymethylglutaryl-coenzyme A reductase in primary cultured rat hepatocytes and in rat liver.
Kocarek TA; Reddy AB
Drug Metab Dispos; 1996 Nov; 24(11):1197-204. PubMed ID: 8937853
[TBL] [Abstract][Full Text] [Related]
14. Effect of 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitors (statins) on tissue paraoxonase 1 and plasma platelet activating factor acetylhydrolase activities.
Bełtowski J; Wójcicka G; Jamroz A
J Cardiovasc Pharmacol; 2004 Jan; 43(1):121-7. PubMed ID: 14668577
[TBL] [Abstract][Full Text] [Related]
15. Protective effect of fluvastatin on degradation of apolipoprotein B by a radical reaction in human plasma.
Aoki S; Ikeda K; Yamamura M; Kojo S
Biol Pharm Bull; 2001 Feb; 24(2):123-6. PubMed ID: 11217077
[TBL] [Abstract][Full Text] [Related]
16. Tissue-selective inhibition of sterol synthesis in mice by pravastatin sodium after a single or repeated oral administrations.
Koga T; Kikuchi T; Miyazaki A; Koike H
Lipids; 1995 Aug; 30(8):775-9. PubMed ID: 7475995
[TBL] [Abstract][Full Text] [Related]
17. Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: comparison with selected HMG-CoA reductase inhibitors.
Bocan TM; Ferguson E; McNally W; Uhlendorf PD; Bak Mueller S; Dehart P; Sliskovic DR; Roth BD; Krause BR; Newton RS
Biochim Biophys Acta; 1992 Jan; 1123(2):133-44. PubMed ID: 1739744
[TBL] [Abstract][Full Text] [Related]
18. Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase.
Corsini A; Mazzotti M; Raiteri M; Soma MR; Gabbiani G; Fumagalli R; Paoletti R
Atherosclerosis; 1993 Jun; 101(1):117-25. PubMed ID: 8216498
[TBL] [Abstract][Full Text] [Related]
19. Antioxidative potential of fluvastatin via the inhibition of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity.
Bandoh T; Sato EF; Mitani H; Nakashima A; Hoshi K; Inoue M
Biol Pharm Bull; 2003 Jun; 26(6):818-22. PubMed ID: 12808293
[TBL] [Abstract][Full Text] [Related]
20. Hep-G2 cells and primary rat hepatocytes differ in their response to inhibitors of HMG-CoA reductase.
Shaw MK; Newton RS; Sliskovic DR; Roth BD; Ferguson E; Krause BR
Biochem Biophys Res Commun; 1990 Jul; 170(2):726-34. PubMed ID: 2166504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
